Earnings Ahead

VRDN - Miragen Therapeutics Inc

23.78 0.175 0.74

Miragen Therapeutics Inc

Miragen Therapeutics Inc

About

Profile

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies.


Headquarters


Intraday

High
-
Low
-

52-week

High
-
Low
-

VRDN



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Viridian Therapeutics GAAP EPS of -$1.61 misses by $0.59, revenue of $0.1M in-line
  • Viridian Therapeutics Q1 2023 Earnings Preview
  • Viridian Therapeutics partners with Enable Injections for wearable drug delivery system development
  • Viridian initiated at overweight at Wells Fargo on thyroid eye disease asset potential
  • Viridian Therapeutics a new buy at Stifel on Tepezza success, pipeline
  • Viridian Therapeutics GAAP EPS of -$1.13 misses by $0.40, revenue of $0.1M misses by $0.36M
  • Viridian gets new operations chief
  • Viridian adds 16% after low dose data for thyroid eye disease candidate
  • Viridian Therapeutics initiated at buy at Needham on lead asset for thyroid eye disease
  • Horizon Therapeutics jumps 31% as analysts comment on potential deal size
  • Viridian Therapeutics GAAP EPS of -$0.86 beats by $0.12, revenue of $1.19M beats by $0.93M
  • Viridian Therapeutics Q3 2022 Earnings Preview
  • Viridian Therapeutics board compensation committee approves inducement grants
  • Viridian slips on pricing $270M stock offering
  • Viridian Therapeutics stock gains on securities offering
  • Viridian hits 52-week high on data for thyroid eye disease candidate
  • Hot Stocks: VRDN surges 60% on clinical data; TXMD, SNDL rise on earnings; U falls after rejecting APP offer
  • Viridian stock soars 39% as thyroid eye disease drug shows promise in trial
  • Viridian Therapeutics GAAP EPS of -$1.06 misses by $0.17, revenue of $0.26M beats by $0.03M
  • Viridian Therapeutics Q2 2022 Earnings Preview

Earnings History

Date EPS / Forecast Revenue / Forecast
November 4, 2021 -1.25 / -1.25 208K / 454.2K
August 11, 2021 -2.21 / -1.36 1.09M / - Beat!
May 6, 2021 -2.91 / -0.756 1.45M / - Beat!
March 25, 2021 -23.07 / -1.7 54K / 80K
November 10, 2020 -1.5 / -1.99 - / -
August 5, 2020 -1.8 / -0.17 168K / 645.25K
May 7, 2020 -2.7 / -0.19 828K / 582.5K Beat!
March 11, 2020 -4.65 / -0.25 880K / 728.5K Beat!
Date Price Open High Low Vol Change ER
May 23, 2023 24.88 24.67
25.17
24.45
768K 0.48%
May 22, 2023 24.76 23.27
24.87
23
1.2M 7.23%
May 19, 2023 23.09 22.94
23.37
22.59
465K 2.30%
May 18, 2023 22.57 22.81
23
21.96
471K -1.48%
May 17, 2023 22.91 23.47
23.47
22.5
429K -2.18%
 
May 16, 2023 23.42 23.02
23.61
22.8
1.1M -0.04%
May 15, 2023 23.43 23.59
24.42
23.32
1.0M 0%
May 12, 2023 23.43 23.85
24.36
23.37
521K -1.72%
May 11, 2023 23.84 25.22
25.64
23.51
787K -6.03%
May 10, 2023 25.37 24.73
26.08
23.5
1.0M -1.21%
May 9, 2023 25.68 25.46
26.06
24.78
773K 0.75%
May 8, 2023 25.49 26.37
26.41
24.89
833K -3.08%
May 5, 2023 26.3 27.78
28
26.26
679K -4.19%
May 4, 2023 27.45 27.79
28.29
26.61
560K -1.22%
May 3, 2023 27.79 28.07
28.34
27.7
584K -0.36%
May 2, 2023 27.89 28.52
28.99
27.51
713K -2.62%
May 1, 2023 28.64 28.01
28.97
28
639K 2.18%
Apr 28, 2023 28.03 27.57
28.46
27.29
612K 1.01%
Apr 27, 2023 27.75 27.71
28.17
27.58
268K 0.43%
Apr 26, 2023 27.63 27.99
28.21
27.13
402K -2.09%
Apr 25, 2023 28.22 29.09
29.56
27.94
455K -2.96%
Apr 24, 2023 29.08 29.57
30.3
28.8
311K -1.99%
Apr 21, 2023 29.67 28.58
30.03
28.5
425K 3.24%
Apr 20, 2023 28.74 29.18
29.95
28.67
557K -1.68%
Apr 19, 2023 29.23 28.64
29.89
28.23
842K 2.35%
Apr 18, 2023 28.56 27.58
28.62
26.65
827K 6.65%
Apr 17, 2023 26.78 25.94
27.19
25.81
1.3M 6.27%
Apr 14, 2023 25.2 26.16
26.31
25.13
289K -3.96%
Apr 13, 2023 26.24 25.9
27.03
25.85
631K 4.79%
Apr 12, 2023 25.04 24.81
25.55
24.5
544K 0.04%
Apr 11, 2023 25.03 24.7
25.27
24.46
367K 1.46%
Apr 10, 2023 24.67 25.22
25.58
24.41
649K -2.91%
Apr 6, 2023 25.41 25.01
25.59
24.66
338K 1.97%
Apr 5, 2023 24.92 25.17
25.58
24.61
357K -1.39%
Apr 4, 2023 25.27 25.34
25.6
24.61
429K -0.63%
Apr 3, 2023 25.43 25.43
25.81
25.1
699K -0.04%
Mar 31, 2023 25.44 25.24
26.01
25.21
738K 1.60%
Mar 30, 2023 25.04 25.99
26.04
24.76
627K -2.23%
Mar 29, 2023 25.61 25.28
25.74
25.1
285K 2.28%
Mar 28, 2023 25.04 25.61
25.94
25.02
209K -2.3%
Mar 27, 2023 25.63 25.61
26.26
25.46
422K -0.43%
Mar 24, 2023 25.74 25.42
25.86
25.03
318K 0.94%
Mar 23, 2023 25.5 26.06
26.13
25.02
442K -1.35%
Mar 22, 2023 25.85 26.76
27.21
25.77
459K -3.26%
Mar 21, 2023 26.72 28.25
28.48
26.7
350K -4.71%
Mar 20, 2023 28.04 27.43
28.17
26.76
561K 2.15%
Mar 17, 2023 27.45 28.57
28.75
26.66
2.0M -4.02%
Mar 16, 2023 28.6 28.15
28.67
27.22
340K 0.46%
Mar 15, 2023 28.47 27.87
28.68
27.87
421K -0.21%
Mar 14, 2023 28.53 30.16
31.1
27.96
594K -1.11%
Mar 13, 2023 28.85 28.09
29.37
28.09
589K 1.55%
Mar 10, 2023 28.41 29.42
29.42
27.95
683K -3.07%
Mar 9, 2023 29.31 29.81
29.81
28.23
705K -0.54%
Mar 8, 2023 29.47 28.91
33
27.8
1.6M -10.48%
Mar 7, 2023 32.92 32.46
33.16
32.35
377K 0.83%
Mar 6, 2023 32.65 32.85
32.85
32.1
252K -0.94%
Mar 3, 2023 32.96 32.68
33.31
32.48
416K 1.26%
Mar 2, 2023 32.55 32.84
32.9
31.91
410K -1.54%
Mar 1, 2023 33.06 32.96
33.21
32.68
355K 0.92%
Feb 28, 2023 32.76 32.49
33.51
32.49
341K 0%